Health Canada will approve Pfizer’s antiviral Paxlovid, an antiviral drug that can reduce the risk of hospitalizations and death by up to 89%.
Posted at 8:32
Updated at 8:51 a.m.
This is the information relayed by Radio-Canada and on the 98.5 FM broadcast Since you have to get up Monday morning. The announcement could be made on Monday, it says.
Paxlovid is an antiviral drug from Pfizer that reduces COVID-19 hospitalizations in vulnerable people. The pill can be administered at home.
Ottawa has approximately one million doses of this treatment already in use in the United States and Europe.
Strong efficiency
Within 28 days of infection, only 0.8% of study participants who received treatment were hospitalized (3 of 389 patients), compared to 7.0% of patients who received placebo (27 of 385 patients). ).
No deaths were reported in patients who received the treatment, compared to 10 deaths in patients in the placebo group.
Administration of the treatment developed by Pfizer consists of a combination of two pills, taken twice a day for five days.
More details to come.